MCID: OLF005
MIFTS: 44

Olfactory Neuroblastoma malady

Categories: Rare diseases, Neuronal diseases, Cancer diseases, Respiratory diseases, Smell/Taste diseases

Aliases & Classifications for Olfactory Neuroblastoma

Aliases & Descriptions for Olfactory Neuroblastoma:

Name: Olfactory Neuroblastoma 12 50 56 14 69
Esthesioneuroblastoma 12 50 56 52
Paranasal Sinus Olfactory Neuroblastoma 12
Esthesioneuroblastoma, Olfactory 42
Olfactory Esthesioneuroblastoma 12
Esthesioneuroepithelioma [dup] 12
Esthesioneuroepithelioma 12
Asthesioneuroblastoma 12

Characteristics:

Orphanet epidemiological data:

56
esthesioneuroblastoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Adult,Elderly;

Classifications:

Orphanet: 56  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:369
MeSH 42 D018304
NCIt 47 C3789 C6016
Orphanet 56 ORPHA1957
ICD10 via Orphanet 34 C30.0
UMLS 69 C0206717

Summaries for Olfactory Neuroblastoma

NIH Rare Diseases : 50 olfactory neuroblastoma is a rare cancer of the upper part of the nasal cavity called the cribiform plate, which is a bone deep in the skull between the eyes, and above the ethmoid sinuses. it accounts for about 5% of all cancers of the nasal cavity and paranasal sinuses. it develops in nerve tissue associated with the sense of smell (olfactory nerve). it can occur at any age, but typically is found in adulthood. symptoms may be nonspecific and include a blockage of the nasal passageways due to the tumor, facial pain, runny nose, and nosebleeds. treatment usually includes surgery to remove the tumor, radiation therapy, and sometimes chemotherapy. last updated: 6/29/2016

MalaCards based summary : Olfactory Neuroblastoma, also known as esthesioneuroblastoma, is related to neuroblastoma and nasal cavity olfactory neuroblastoma. An important gene associated with Olfactory Neuroblastoma is SYP (Synaptophysin), and among its related pathways/superpathways are Neuroscience and Transcriptional misregulation in cancer. The drugs Fentanyl and Cevimeline have been mentioned in the context of this disorder. Affiliated tissues include eye, bone and lung, and related phenotype is Decreased shRNA abundance (Z-score < -2).

Related Diseases for Olfactory Neuroblastoma

Diseases related to Olfactory Neuroblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 175)
id Related Disease Score Top Affiliating Genes
1 neuroblastoma 31.3 ENO2 NGFR NTRK1 SYP
2 nasal cavity olfactory neuroblastoma 12.1
3 sm-ahnmd 10.3 CHGA ENO2
4 granulocytopenia 10.3 CHGA ENO2
5 infiltrating renal pelvis transitional cell carcinoma 10.3 ENO2 SYP
6 skeletal-extraskeletal angiomatosis 10.3 ENO2 SYP
7 glomus tumor 10.3 ENO2 SYP
8 pemphigus foliaceus 10.3 ENO2 SYP
9 parietal lobe neoplasm 10.3 CHGA ENO2
10 autosomal recessive stickler syndrome 10.3 ENO2 SYP
11 urinary tract obstruction 10.3 CHGA ENO2
12 ampullary signet ring cell adenocarcinoma 10.3 ENO2 SYP
13 nephrogenic adenoma of urinary bladder 10.3 ENO2 SYP
14 spinal stenosis 10.3 CHGA ENO2
15 gastrointestinal system benign neoplasm 10.3 CHGA ENO2
16 peroneal nerve paralysis 10.3 CHGA SYP
17 myelinoclastic diffuse sclerosis 10.3 ENO2 S100B
18 blood group incompatibility 10.3 ENO2 SYP
19 brain stem ependymoma 10.3 CHGA SYP
20 benign schwannoma 10.3 ENO2 S100B
21 non specific chronic endometritis 10.3 CHGA SYP
22 extrahepatic biliary papillomatosis 10.3 CHGA SYP
23 epithelioid malignant peripheral nerve sheath tumor 10.3 CHGA SYP
24 cartilage cancer 10.3 CHGA SYP
25 villous adenocarcinoma 10.3 CHGA SYP
26 renal pelvis adenocarcinoma 10.3 CHGA SYP
27 barre-lieou syndrome 10.2 CHGA SYP
28 gastric duplication cysts 10.2 CHGA SYP
29 gallbladder pleomorphic giant cell adenocarcinoma 10.2 ENO2 SYP
30 adult epithelioid sarcoma 10.2 ENO2 SYP
31 diffuse cutaneous mastocytosis 10.2 CHGA SYP
32 thymoma 10.2 ENO2 SYP
33 main bronchus cancer 10.2 CHGA SYP
34 thoracic benign neoplasm 10.2 ENO2 SYP
35 microsporidiosis 10.2 ENO2 SYP
36 gamma heavy chain disease 10.2 ENO2 SYP
37 cavernous hemangioma of face 10.2 CHGA SYP
38 trombiculiasis 10.2 CHGA S100B
39 adult botryoid rhabdomyosarcoma 10.2 CHGA SYP
40 exudative glomerulonephritis 10.2 CHGA SYP
41 hepatorenal syndrome 10.2 CHGA SYP
42 adult endodermal sinus tumor 10.2 ENO2 NGFR
43 acalculous cholecystitis 10.2 CHGA SYP
44 vulvar alveolar soft part sarcoma 10.2 ENO2 SYP
45 brain stem astrocytic neoplasm 10.2 CHGA SYP
46 calcific tendinitis 10.2 CHGA SYP
47 corneal intraepithelial neoplasm 10.2 S100B SYP
48 skin glomus tumor 10.2 ENO2 S100B
49 bone marrow cancer 10.2 CHGA SYP
50 hypoparathyroidism-intellectual disability-dysmorphism syndrome 10.2 S100B SYP

Graphical network of the top 20 diseases related to Olfactory Neuroblastoma:



Diseases related to Olfactory Neuroblastoma

Symptoms & Phenotypes for Olfactory Neuroblastoma

GenomeRNAi Phenotypes related to Olfactory Neuroblastoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-111 9.64 SSTR2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 9.64 CHGA
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.64 NTRK1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.64 SSTR2
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-20 9.64 NTRK1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.64 SSTR2
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 9.64 EWSR1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.64 EWSR1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.64 SSTR2 CHGA EWSR1 NTRK1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.64 SSTR2
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.64 NTRK1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-61 9.64 CHGA
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 9.64 CHGA
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.64 SSTR2
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.64 EWSR1
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 9.64 EWSR1
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.64 EWSR1
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 9.64 SSTR2

Drugs & Therapeutics for Olfactory Neuroblastoma

Drugs for Olfactory Neuroblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 144)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
3
Fluconazole Approved Phase 2, Phase 3 86386-73-4 3365
4
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
5
Megestrol acetate Approved, Vet_approved Phase 3 595-33-5 11683
6
Doxepin Approved Phase 3 1668-19-5 667477 667468
7
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
8
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
9 Liver Extracts Phase 3,Phase 2,Phase 1
10 Anti-Infective Agents Phase 2, Phase 3,Phase 1
11 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
12 Adjuvants, Anesthesia Phase 3
13 Analgesics Phase 3
14 Analgesics, Opioid Phase 3
15 Anesthetics Phase 3
16 Anesthetics, General Phase 3
17 Anesthetics, Intravenous Phase 3
18 Central Nervous System Depressants Phase 3
19 Narcotics Phase 3
20 pancreatic polypeptide Phase 3,Phase 1
21 Peripheral Nervous System Agents Phase 3
22 Autonomic Agents Phase 3
23 Cholinergic Agents Phase 3
24 Neurotransmitter Agents Phase 3
25 Antifungal Agents Phase 2, Phase 3,Phase 1
26 Cytochrome P-450 CYP2C9 Inhibitors Phase 2, Phase 3
27 Hormone Antagonists Phase 2, Phase 3,Phase 1
28 Hormones Phase 2, Phase 3,Phase 1
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 1
30 Steroid Synthesis Inhibitors Phase 2, Phase 3
31 Antineoplastic Agents, Hormonal Phase 3
32 Appetite Stimulants Phase 3
33 Central Nervous System Stimulants Phase 3
34 Contraceptive Agents Phase 3
35 Contraceptives, Oral Phase 3
36
Megestrol Phase 3 3562-63-8 19090 3080587
37 Antimitotic Agents Phase 3,Phase 2,Phase 1
38 Antidepressive Agents Phase 3
39 Antidepressive Agents, Tricyclic Phase 3
40 Histamine Antagonists Phase 3
41
Histamine Phosphate Phase 3 51-74-1 65513
42 Psychotropic Drugs Phase 3
43 Cola Nutraceutical Phase 3,Phase 2,Phase 1
44
Indinavir Approved Phase 2 150378-17-9 5362440
45
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
46
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
47
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
48
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333
49
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
50
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904

Interventional clinical trials:

(show top 50) (show all 65)
id Name Status NCT ID Phase
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
2 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
3 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3
4 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3
5 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3
6 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Active, not recruiting NCT01156142 Phase 3
7 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3
8 Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer Unknown status NCT00003489 Phase 2
9 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
10 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2
11 Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Completed NCT00101348 Phase 1, Phase 2
12 High-dose ICE With Amifostine Completed NCT00003657 Phase 2
13 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2
14 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2
15 Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer Completed NCT00448552 Phase 2
16 Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor Completed NCT00021047 Phase 1, Phase 2
17 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2
18 Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer Completed NCT00007982 Phase 2
19 Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer Completed NCT00509665 Phase 2
20 Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer Completed NCT00021333 Phase 2
21 Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients Recruiting NCT02099188 Phase 2
22 Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients Recruiting NCT02099175 Phase 2
23 Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy Recruiting NCT01586767 Phase 2
24 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Recruiting NCT01806675 Phase 1, Phase 2
25 MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer Unknown status NCT00984074 Phase 1
26 Functional MRI in Finding Hypoxia in Patients Undergoing Chemotherapy and Radiation Therapy for Stage III or Stage IV Head and Neck Cancer Unknown status NCT00896350 Phase 1
27 Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer Completed NCT01637194 Phase 1
28 Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00023959 Phase 1
29 Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors Completed NCT00089362 Phase 1
30 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1
31 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1
32 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1
33 Head & Neck Cancer Survivorship: Physical and Functional Status Completed NCT00751816 Phase 1
34 Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors Completed NCT01172028 Phase 1
35 Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Completed NCT00045006 Phase 1
36 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1
37 Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer Completed NCT00019110 Phase 1
38 Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors Completed NCT00010023 Phase 1
39 Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors Completed NCT00006036 Phase 1
40 Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer Completed NCT00004065 Phase 1
41 Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function Completed NCT00002901 Phase 1
42 NGR-TNF in Treating Patients With Advanced Solid Tumors Completed NCT00098943 Phase 1
43 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1
44 Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1
45 SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck Completed NCT00005647 Phase 1
46 Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer Active, not recruiting NCT00470496 Phase 1
47 Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin Terminated NCT00023790 Phase 1
48 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
49 S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors Withdrawn NCT00937417 Phase 1
50 Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer Unknown status NCT00499733

Search NIH Clinical Center for Olfactory Neuroblastoma

Cochrane evidence based reviews: esthesioneuroblastoma, olfactory

Genetic Tests for Olfactory Neuroblastoma

Anatomical Context for Olfactory Neuroblastoma

MalaCards organs/tissues related to Olfactory Neuroblastoma:

39
Eye, Bone, Lung, Breast, Thyroid, Lymph Node, Pituitary

Publications for Olfactory Neuroblastoma

Articles related to Olfactory Neuroblastoma:

(show top 50) (show all 273)
id Title Authors Year
1
Proton beam therapy for olfactory neuroblastoma. ( 28062086 )
2017
2
Olfactory neuroblastoma: 14-year experience at an Australian tertiary centre and the role for longer-term surveillance. ( 27917732 )
2016
3
Olfactory neuroblastoma: A clinicopathological experience of a rare entity from Pakistan. ( 27375694 )
2016
4
Aberrant Pattern of Cytokeratin Expression in Olfactory Neuroblastoma: A Potential Diagnostic Pitfall. ( 27392748 )
2016
5
Recurrent olfactory neuroblastoma in remote leptomeninges, mimicking intracranial meningioma. ( 27609444 )
2016
6
Expression pattern of ISL-1, TTF-1 and PAX5 in olfactory neuroblastoma. ( 27543867 )
2016
7
Endoscopic Endonasal Management of Olfactory Neuroblastoma: A retrospective analysis of 10 patients with quality of life measures. ( 26899467 )
2016
8
Olfactory neuroblastoma: A frontal lobe disorder and a runny nose. ( 27022175 )
2016
9
Long-Term Prognostic Analysis after Endoscopic Endonasal Surgery for Olfactory Neuroblastoma: A Retrospective Study of 13 Cases. ( 27806104 )
2016
10
Olfactory neuroblastoma followed by emergency surgery for symptomatic intradural spinal metastasis: A case report. ( 27625887 )
2016
11
Neuroendocrine Neoplasms of the Sinonasal Tract: Neuroendocrine Carcinomas and Olfactory Neuroblastoma. ( 26830400 )
2016
12
Syndrome of inappropriate antidiuretic hormone secretion in a case of olfactory neuroblastoma without anti-diuretic hormone immunoreactivity: A case report and review of the literature. ( 28010942 )
2016
13
Role of (18) F-FDG PET/CT differentiating olfactory neuroblastoma from sinonasal undifferentiated carcinoma. ( 27481043 )
2016
14
Bilateral Synchronous Ectopic Ethmoid Sinus Olfactory Neuroblastoma: A Case Report. ( 27097989 )
2016
15
Genetic and molecular alterations in olfactory neuroblastoma - implications for pathogenesis, prognosis and treatment. ( 27256979 )
2016
16
Recurrent Olfactory Neuroblastoma Treated With Cetuximab and Sunitinib: A Case Report. ( 27149458 )
2016
17
Ectopic primary olfactory neuroblastoma of the maxillary sinus. ( 27180059 )
2016
18
An isolated orbital mass with proptosis and diplopia: an uncommon metastasis from intracranial olfactory neuroblastoma in a chinese patient. ( 27601919 )
2016
19
Imaging Characteristics of Olfactory Neuroblastoma (Esthesioneuroblastoma). ( 26949582 )
2016
20
Olfactory Neuroblastoma: Fate of the Neck-A Long-term Multicenter Retrospective Study. ( 26671900 )
2016
21
Paraneoplastic syndromes in olfactory neuroblastoma. ( 26199564 )
2015
22
Esthesioneuroblastoma (olfactory neuroblastoma) treated with 111In-octreotide and 177Lu-DOTATATE PRRT. ( 25674857 )
2015
23
Minimally invasive resection of olfactory neuroblastoma by transnasal endoscopy. ( 26322455 )
2015
24
Comparison of outcomes for open versus endoscopic approaches for olfactory neuroblastoma: A systematic review and individual participant data meta-analysis. ( 26514662 )
2015
25
Olfactory neuroblastoma: the long-term outcome and late toxicity of multimodal therapy including radiotherapy based on treatment planning using computed tomography. ( 25888953 )
2015
26
An endoscopic endonasal approach for early-stage olfactory neuroblastoma: an evaluation of 2 cases with minireview of literature. ( 25650131 )
2015
27
Non-contiguous meningeal metastases of olfactory neuroblastoma. ( 26376653 )
2015
28
Olfactory neuroblastoma: A case report. ( 26788185 )
2015
29
Olfactory Neuroblastoma: A Case Report. ( 26316323 )
2015
30
Metastatic follicular thyroid carcinoma masquerading as olfactory neuroblastoma: with skull-base, cranium, paranasal sinus, lung, and diffuse bone metastases. ( 25569410 )
2015
31
Comparative genomic hybridization on microarray (a-CGH) in olfactory neuroblastoma: Analysis of ten cases and review of the literature. ( 26355525 )
2015
32
Multidisciplinary treatment of olfactory neuroblastoma: Patterns of failure and management of recurrence. ( 25749259 )
2015
33
Olfactory neuroblastoma and olfactory ventricle. A case report. ( 25196619 )
2014
34
Erratum. The Neuroradiology Journal 27: 452-455, 2014 - doi: 10.15274/NRJ-2014-10060 - www.centauro.it. Olfactory Neuroblastoma and Olfactory Ventricle. ( 25260211 )
2014
35
Olfactory neuroblastoma with focal ganglioneuroblastic differentiation: a case report with literature review. ( 25291869 )
2014
36
Treatment of olfactory neuroblastoma: a new approach. ( 24934414 )
2014
37
Aggressive primary olfactory neuroblastoma of the sphenoclival region: A case report and literature review. ( 25215962 )
2014
38
Long-term results of endoscopic assisted cranionasal resection for olfactory neuroblastoma - single centre experience of 14 patients. ( 25522034 )
2014
39
Olfactory Neuroblastoma With Hyponatremia. ( 24687825 )
2014
40
Long-term follow-up using 18F-FDG PET/CT for postoperative olfactory neuroblastoma. ( 24751700 )
2014
41
Of mice and men: olfactory neuroblastoma among animals and humans. ( 25041470 )
2014
42
Case report: recurrent olfactory neuroblastoma nasal cavity in young boy refractory to chemotherapy with remission after radiotherapy and sparing of left eye. ( 25316398 )
2014
43
Olfactory neuroblastoma behavior inside and outside the olfactory cleft. ( 25218517 )
2014
44
A case of olfactory neuroblastoma detected by (18)F-FDG PET/CT. ( 24662664 )
2014
45
Olfactory neuroblastoma: a 35-year experience and suggested follow-up protocol. ( 24347437 )
2013
46
Syndrome of inappropriate antidiuretic hormone secretion associated with olfactory neuroblastoma. ( 24220439 )
2013
47
Odorant receptor genes are expressed in olfactory neuroblastoma. ( 24065686 )
2013
48
Radiation-associated meningioma in the elderly: development of meningioma with olfactory neuroblastoma recurrence 10 years after irradiation. ( 24247807 )
2013
49
(CS) Due to Ectopic Cushing's Syndrome Adrenocorticotrophic Hormone (ACTH) Production by Olfactory Neuroblastoma (ON): Case Report and Literature Review. ( 24246335 )
2013
50
Olfactory neuroblastoma (esthesioneuroblastoma): towards minimally invasive surgery and multi-modality treatment strategies - an updated critical review of the current literature. ( 24065464 )
2013

Variations for Olfactory Neuroblastoma

Copy number variations for Olfactory Neuroblastoma from CNVD:

7 (show all 31)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 31526 1 28000000 30200000 Gain Olfactory neuroblastoma
2 34250 1 5400000 7200000 Gain Olfactory neuroblastoma
3 41470 10 18700000 22600000 Gain Olfactory neuroblastoma
4 63735 12 120700000 125900000 Gain Olfactory neuroblastoma
5 74688 13 110300000 115169878 Gain CUL4A Olfactory neuroblastoma
6 74689 13 110300000 115169878 Gain TFDP1 Olfactory neuroblastoma
7 75167 13 17900000 115169878 Gain Olfactory neuroblastoma
8 77744 13 47300000 55300000 Gain Olfactory neuroblastoma
9 79881 13 79000000 87700000 Gain Olfactory neuroblastoma
10 91527 15 31200000 33600000 Gain Olfactory neuroblastoma
11 101890 16 47000000 52600000 Gain Olfactory neuroblastoma
12 150427 20 1 27500000 Gain Olfactory neuroblastoma
13 151980 20 27500000 63025520 Gain Olfactory neuroblastoma
14 152120 20 29400000 37600000 Gain Olfactory neuroblastoma
15 154980 20 5100000 12100000 Gain Olfactory neuroblastoma
16 155529 20 56500000 63025520 Gain BRK Olfactory neuroblastoma
17 159453 21 42600000 48129895 Gain Olfactory neuroblastoma
18 163221 22 25900000 29600000 Gain Olfactory neuroblastoma
19 179990 4 1 6000000 Gain Olfactory neuroblastoma
20 181394 4 120800000 191154276 Gain Olfactory neuroblastoma
21 184608 4 17800000 48200000 Gain Olfactory neuroblastoma
22 187607 4 52700000 59500000 Gain Olfactory neuroblastoma
23 190046 4 82400000 93700000 Gain Olfactory neuroblastoma
24 196156 5 159900000 168500000 Gain Olfactory neuroblastoma
25 196538 5 168500000 180915260 Gain Olfactory neuroblastoma
26 213457 6 46200000 51800000 Gain Olfactory neuroblastoma
27 227898 7 72200000 77500000 Gain FZD9 Olfactory neuroblastoma
28 227899 7 72200000 77500000 Gain LIMK1 Olfactory neuroblastoma
29 228591 7 77500000 86400000 Gain Olfactory neuroblastoma
30 251884 9 33200000 36300000 Gain Olfactory neuroblastoma
31 257109 X 1 155270560 Gain Olfactory neuroblastoma

Expression for Olfactory Neuroblastoma

Search GEO for disease gene expression data for Olfactory Neuroblastoma.

Pathways for Olfactory Neuroblastoma

Pathways related to Olfactory Neuroblastoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.53 ENO2 NGFR NTRK1 S100B SYP
2 11.39 EWSR1 NGFR NTRK1

GO Terms for Olfactory Neuroblastoma

Biological processes related to Olfactory Neuroblastoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 learning or memory GO:0007611 9.16 NTRK1 S100B
2 regulation of neuronal synaptic plasticity GO:0048168 8.96 S100B SYP
3 neurotrophin TRK receptor signaling pathway GO:0048011 8.62 NGFR NTRK1

Molecular functions related to Olfactory Neuroblastoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nerve growth factor binding GO:0048406 8.96 NGFR NTRK1
2 neurotrophin binding GO:0043121 8.62 NGFR NTRK1

Sources for Olfactory Neuroblastoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....